Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: The importance of measuring TNF-alpha

Inflammopharmacology

Volumn 14, Issue 5-6, 2006, Pages 256-259

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Aspirin; Cyclooxygenase inhibitors; Interleukin 6; Myeloma; Tumor necrosis factor alpha

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CELECOXIB; CURCUMIN; DEXAMETHASONE; DICLOFENAC; DOXORUBICIN; ETANERCEPT; GROWTH FACTOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 6; NAPROXEN; PHENYLBUTAZONE; PROSTAGLANDIN SYNTHASE INHIBITOR; RESVERATROL; SULINDAC; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

APOPTOSIS; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE EXACERBATION; DNA REPLICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFORMATION PROCESSING; LOW DRUG DOSE; MONOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SURVIVAL RATE;

APOPTOSIS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845473864     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-006-1532-6     Document Type: Conference Paper

References (22)

1. Ashikawa, K., Shishodia, S., Fokt, I. et al. (2004). Evidence that activation of NFkB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 67(2), 353-364.
2. Baz, R., Hussein, M. A. (2006). Does low-dose aspirin have antineoplastic effects in multiple myeloma? Br. J. Haematol. 134(3), 349-350.
3. Bien, S., Ritter, C. A., Gratz, M. et al. (2004). NFkB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol. Pharmacol. 65(5), 1092-1102.
4. Cambell, K. J., Perkins, N. D. (2006). Regulation of NFkB function. Biochem. Soc. Symp. 73, 165-180.
5. Chanan-Khan, A. A. (2004). Bcl-2 antisense therapy in multiple myeloma. Oncology (Williston Park). 13 Suppl 10, 21-24.
6. Das, K. C., White, C. W. (1997). Activation of NFkB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272(23), 14914-14920.
7. Din, F. V., Stark, L. A., Dunlop, M. G. (2005). Aspirin-induced nuclear translocation of NFkB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. Br. J. Cancer. 92(6), 1137-1143.
8. Fassas, A. B., Rapoport, A. P., Bolanos-Meade, J. et al. (2001). Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leuk. Lymphoma. 42(6), 1323-1328.
9. Jurisic, V., Colovic, M. (2002). Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med. Oncol. 19(3), 133-139.
10. Kane, R. C., Farrell, A. T., Sridhara, R. et al. (2006). United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 12(10), 2955-2960.
11. Kast, R. E. (2000). Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing TNF. Biomed Pharmacother. 54, 168-169.
12. Kast, R. E. (2000). Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. Int. J. Immunopharmacol. 22, 1001-1006.
13. Kast, R. E. (2003). Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation. Mol. Immunol. 40, 297-303.
14. Kast, R. E. (2005). Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities-the role of bupropion. Leuk Res. 29, 1459-1463.
15. Kast, R. E. (2006). Aspirin use in myeloma: A note of caution regarding potential TNF-alpha elevation. Brit. J. Haematol. 133, 216.
16. O'Connor, O. A., Smith, E. A., Toner, L. E. et al. (2006). The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin. Cancer Res. 12(9), 2902-2911.
17. Slomiany, B. L., Slomiany, A. (2000). Aspirin ingestion impairs oral mucosal ulcer healing by inducing membrane-bound TNF-alpha release. IUBMB Life, 50(6), 391-395.
18. Slomiany, B. L., Piotrowski, J., Slomiany, A. (2001). Up-regulation of gastric mucosal inflammatory responses to H. pylori and LPS by aspirin but not indomethacin. J. Endotoxin Res. 7, 203-209.
19. Strozyk, E., Poppelmann, B., Schwarz, T. et al. (2006). Differential effects of NFkB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene (Epub ahead of print).
20. Takada, Y., Bhardwaj, A., Potdar, P. et al. (2004). Nonsteroidal anti-inflammatory agents differ in their ability to suppress NFkB activation, inhibition of expression of cyclooxygenase-2 and cyclin Dl, and abrogation of tumor cell proliferation. Oncogene 23(57), 9247-9258.
21. Tergaonkar, V., Bottero, V., Ikawa, M. et al. (2003). IkappaB kinase-independent IkappaBalpha degradation pathway: functional NFkB activity and implications for cancer therapy. Mol. Cell Biol. 23(22), 8070-8083.
22. Tsimberidou, A. M., Waddelow, T., Kantarjian, H. M. et al. (2003). Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 27, 375-380.